BusinessPeregrine Pharmaceuticals to Report Financial Results for Second Quarter of Fiscal Year 2018 After Market Close on December 11, 2017By Nasdaq OMXDec 4, 2017, 9:05 PM UTC
BusinessAvid Bioservices Announces Appointment of Tracy Kinjerski as Vice President of Business OperationsBy Nasdaq OMXNov 29, 2017, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement AgreementBy Nasdaq OMXNov 28, 2017, 1:05 PM UTC
BusinessCytovance Biologics, Inc. announces Bexion Pharmaceuticals Inc. has chosen Cytovance to manufacture the protein component and active ingredient of Bexion’s first clinical compound, BXQ-350By Nasdaq OMXNov 28, 2017, 10:00 AM UTC
BusinessDeacom Delivers the Right Tools for Tower Laboratories to Meet Scaling Customer RequirementsBy Nasdaq OMXOct 31, 2017, 2:30 PM UTC
BusinessAvid Bioservices Expands Manufacturing Capabilities With Installation and Validation of Two MilliporeSigma Mobius® 2,000-Liter Single-Use Bioreactors in Its Myford FacilityBy Nasdaq OMXSep 25, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent DevelopmentsBy Nasdaq OMXSep 11, 2017, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid BioservicesBy Nasdaq OMXSep 11, 2017, 12:05 PM UTC
